Thromboembolic complications after renal transplantation: Results from the randomized trial of cyclosporine v azathioprine-antilymphocyte globulin

S. A. Gruber, M. Pescovitz, R. L. Simmons, J. S. Najarian, N. L. Ascher, W. D. Payne, D. E. Sutherland, B. Elick, D. S. Fryd

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

In a recent retrospective study comparing equal numbers of cyclosporine (CsA)-treated and azathioprine (Aza)-treated non-diabetic, cadaveric allograft recipients, a significantly higher incidence of venous thromboembolism was noted in the CsA group. This analysis stimulated the appearance of several brief conflicting reports by other centers, and we decided to examine whether CsA immunosuppression is indeed a risk factor for thromboembolic disease by comparing the incidence of arterial and venous thromboembolic events in patients entered in a prospective, randomized trial of CsA v Aza-antilymphocyte globulin (ALG).

Original languageEnglish (US)
Pages (from-to)1815-1816
Number of pages2
JournalTransplantation proceedings
Volume19
Issue number1 II
StatePublished - Apr 29 1987

Fingerprint Dive into the research topics of 'Thromboembolic complications after renal transplantation: Results from the randomized trial of cyclosporine v azathioprine-antilymphocyte globulin'. Together they form a unique fingerprint.

Cite this